Orexo AB (publ) (ORXOF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Orexo AB (publ) (ORXOF) with AI Score 50/100 (Hold). Orexo AB (publ) is a Swedish specialty pharmaceutical company focused on developing and commercializing pharmaceuticals and digital therapies, primarily in the fields of opioid dependence and pain management. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Orexo AB (publ) (ORXOF) Healthcare & Pipeline Overview
Orexo AB (publ) develops and commercializes specialty pharmaceuticals and digital therapies, focusing on opioid dependence, pain management, and mental health. With products like Zubsolv and digital therapeutics such as deprexis, Orexo operates in the US, Europe, and the UK, facing competition in the specialty drug and digital health markets.
Investment Thesis
Orexo AB (publ) presents a compelling investment thesis centered on its focus on opioid dependence treatment and digital therapeutics. The company's key value drivers include the continued market penetration of Zubsolv, its sublingual tablet for opioid dependence, and the expansion of its digital therapy offerings, such as deprexis and vorvida. The growth in the digital health market, projected to reach $660 billion by 2027, provides a significant opportunity for Orexo's digital therapeutics. Catalysts for growth include the potential approval and commercialization of its pipeline products, such as OX124 and OX125, for opioid overdose rescue. However, investors should be aware of potential risks, including competition from generic alternatives to Zubsolv and the challenges associated with regulatory approval and market adoption of digital therapies. Orexo's negative profit margin of -33.6% also warrants careful consideration.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.11 billion reflects its position as a smaller player in the specialty pharmaceutical market.
- Negative P/E ratio of -6.38 indicates that the company is currently not profitable.
- Negative profit margin of -33.6% highlights the challenges in achieving profitability, potentially due to high R&D and commercialization costs.
- Negative gross margin of -14.4% suggests that the cost of goods sold exceeds revenue, requiring strategic cost management.
- Beta of 0.83 indicates lower volatility compared to the overall market, suggesting a relatively stable stock.
Competitors & Peers
Strengths
- Specialized focus on opioid dependence and pain management.
- Pipeline of innovative pharmaceutical and digital therapy products.
- Established presence in the United States and Europe.
- Proprietary drug delivery technologies.
Weaknesses
- Negative profit margin and financial performance.
- Reliance on a limited number of key products.
- Competition from larger pharmaceutical companies.
- Dependence on regulatory approvals for pipeline products.
Catalysts
- Upcoming: Potential regulatory approval and commercialization of OX124 and OX125 for opioid overdose rescue.
- Ongoing: Expansion of the digital therapeutics portfolio and market reach.
- Ongoing: Continued growth in the opioid dependence treatment market.
- Upcoming: Strategic partnerships and acquisitions to expand product offerings and geographic presence.
Risks
- Ongoing: Competition from generic alternatives to Zubsolv.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Potential: Product liability claims related to pharmaceutical products.
- Ongoing: Challenges in securing regulatory approval and market adoption of digital therapies.
- Ongoing: Negative profit margin and financial performance.
Growth Opportunities
- Expansion of Digital Therapeutics: Orexo has the opportunity to capitalize on the rapidly growing digital therapeutics market, projected to reach $17.6 billion by 2026. By expanding the reach and functionality of its digital therapies like deprexis and vorvida, Orexo can address unmet needs in mental health and substance abuse treatment, potentially increasing revenue and market share. Success hinges on demonstrating clinical efficacy and securing reimbursement from healthcare providers.
- Pipeline Development and Commercialization: Orexo's pipeline of pharmaceutical products, including OX124 and OX125 for opioid overdose rescue, represents a significant growth opportunity. The market for opioid overdose reversal medications is expanding due to the ongoing opioid crisis. Successful development and commercialization of these products could generate substantial revenue and improve Orexo's financial performance. Regulatory approval timelines and market adoption rates are key factors.
- Geographic Expansion: Orexo currently operates primarily in the United States, Europe, and the United Kingdom. Expanding into new geographic markets, such as Asia-Pacific and Latin America, could significantly increase its customer base and revenue. These regions have growing healthcare needs and increasing adoption of specialty pharmaceuticals and digital health solutions. Market entry strategies and local regulatory requirements need careful consideration.
- Strategic Partnerships and Acquisitions: Orexo can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and enter new markets. Collaborating with other pharmaceutical companies, digital health providers, or research institutions can accelerate innovation and reduce development costs. Identifying suitable partners and negotiating favorable terms are critical for success.
- Lifecycle Management of Existing Products: Orexo can extend the lifecycle of its existing products, such as Zubsolv and Abstral, through various strategies, including developing new formulations, expanding indications, and pursuing patent extensions. This can help maintain market share and generate revenue even as competitors enter the market. Effective patent protection and regulatory strategies are essential.
Opportunities
- Expansion into new geographic markets.
- Growth in the digital health market.
- Strategic partnerships and acquisitions.
- Development of new formulations and indications for existing products.
Threats
- Competition from generic alternatives.
- Changes in healthcare regulations and reimbursement policies.
- Product liability claims.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Patents protecting its pharmaceutical products.
- Proprietary formulations and drug delivery technologies.
- Established relationships with healthcare providers.
- First-mover advantage in certain digital therapy markets.
About ORXOF
Orexo AB (publ) is a Swedish specialty pharmaceutical company founded in 1994 and headquartered in Uppsala, Sweden. The company focuses on developing and commercializing innovative pharmaceuticals and digital therapies, primarily targeting opioid dependence, pain management, and mental health. Orexo's product portfolio includes Zubsolv, a sublingual tablet for the treatment of opioid dependence, designed to reduce abuse potential compared to traditional opioid replacement therapies. Abstral, another key product, addresses breakthrough pain in cancer patients, providing rapid relief through a sublingual formulation. Additionally, Orexo markets Edluar for the treatment of short-term insomnia. Beyond pharmaceuticals, Orexo is actively involved in developing digital therapies. These include deprexis, a digital therapeutic for the treatment of mild to severe depression; vorvida, a solution for alcohol use disorder; and modia, a digital therapy targeting opioid use disorder. These digital products represent a strategic shift towards integrated healthcare solutions, combining pharmacological and behavioral interventions. Orexo also has a pipeline of development products, including OX124 and OX125 for naloxone and nalmefene rescue, respectively, OX640 for allergic reactions, and OX338 for moderate to severe pain. The company operates primarily in the United States, Europe, and the United Kingdom, commercializing its products through a combination of its own sales force and partnerships. Orexo faces competition from other specialty pharmaceutical companies and digital health providers, requiring continuous innovation and strategic market positioning to maintain its competitive edge.
What They Do
- Develops and commercializes pharmaceutical products.
- Offers digital therapies for mental health and substance abuse.
- Focuses on treatments for opioid dependence.
- Provides solutions for breakthrough pain in cancer patients.
- Addresses short-term insomnia with pharmaceutical products.
- Develops medications for allergic reactions and pain management.
Business Model
- Develops and patents pharmaceutical products and digital therapies.
- Commercializes products through its own sales force and partnerships.
- Generates revenue through sales of prescription medications and digital therapy subscriptions.
- Invests in research and development to expand its product pipeline.
Industry Context
Orexo AB (publ) operates within the specialty pharmaceutical and digital health industries. The specialty pharmaceutical market is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The digital health market is experiencing rapid growth, driven by increasing adoption of telehealth and digital therapeutics. Orexo's focus on opioid dependence treatment aligns with the growing need for effective solutions to combat the opioid crisis. Competitors include both traditional pharmaceutical companies and emerging digital health providers. The global digital health market is projected to reach $660 billion by 2027, presenting significant growth opportunities for companies like Orexo.
Key Customers
- Patients suffering from opioid dependence.
- Cancer patients experiencing breakthrough pain.
- Individuals with insomnia.
- Healthcare providers prescribing medications and recommending digital therapies.
- Pharmacies dispensing Orexo's pharmaceutical products.
Financials
Chart & Info
Orexo AB (publ) (ORXOF) stock price: Price data unavailable
Latest News
-
Orexo AB (ORXOF) Q4 2025 Earnings Call Highlights: Strategic Divestment and Financial Resilience
GuruFocus.com · Feb 10, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ORXOF.
Price Targets
Wall Street price target analysis for ORXOF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ORXOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Nikolaj Sorensen
CEO
Nikolaj Sorensen serves as the CEO of Orexo AB (publ). His background includes extensive experience in the pharmaceutical industry, with a focus on commercial strategy and business development. Prior to joining Orexo, he held leadership positions at various pharmaceutical companies, where he was responsible for driving revenue growth and expanding market share. Sorensen's expertise spans across multiple therapeutic areas, including pain management and addiction treatment. His educational background includes advanced degrees in business and marketing.
Track Record: Under Nikolaj Sorensen's leadership, Orexo AB (publ) has focused on expanding its digital therapeutics portfolio and strengthening its position in the opioid dependence treatment market. Key achievements include the commercialization of new digital therapies and the expansion of Zubsolv's market reach. Sorensen has also overseen strategic partnerships aimed at accelerating innovation and expanding the company's geographic footprint. His tenure has been marked by a focus on sustainable growth and improving financial performance.
ORXOF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Orexo AB (publ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Trading on the OTC Other tier carries higher risks compared to exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- Higher potential for fraud and manipulation due to less regulatory oversight.
- Increased risk of delisting or trading suspension.
- OTC Other stocks may not be marginable.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC trading.
- Company has a verifiable business address and contact information.
- Management team has relevant experience in the pharmaceutical industry.
- Company has patents or intellectual property protecting its products.
- Company has partnerships with reputable healthcare organizations.
- Company has a clear business plan and growth strategy.
ORXOF Healthcare Stock FAQ
What does Orexo AB (publ) do?
Orexo AB (publ) is a specialty pharmaceutical company that develops and commercializes pharmaceutical products and digital therapies, primarily focusing on opioid dependence, pain management, and mental health. Its key products include Zubsolv for opioid dependence and digital therapies like deprexis for depression and vorvida for alcohol use disorder. The company operates in the United States, Europe, and the United Kingdom, targeting patients and healthcare providers with its innovative solutions.
What do analysts say about ORXOF stock?
Analyst coverage of ORXOF is limited due to its OTC listing and smaller market capitalization. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability. Growth considerations include the potential for pipeline products and digital therapies to drive future revenue. Analyst consensus is not readily available, and investors should conduct their own due diligence and consider the risks associated with OTC trading.
What are the main risks for ORXOF?
The main risks for ORXOF include competition from generic alternatives to its key products, such as Zubsolv, which could erode market share and revenue. Regulatory risks, such as changes in healthcare policies and reimbursement rates, could also impact the company's financial performance. Additionally, the company faces challenges in securing regulatory approval and market adoption of its digital therapies. The negative profit margin and financial performance also pose a significant risk to investors.
How does Orexo AB (publ) navigate regulatory approval processes?
Orexo AB (publ) navigates regulatory approval processes by adhering to stringent guidelines set by regulatory bodies such as the FDA in the United States and the EMA in Europe. The company invests in clinical trials and data collection to demonstrate the safety and efficacy of its pharmaceutical products and digital therapies. Orexo also engages with regulatory agencies to address any concerns and ensure compliance with applicable regulations. Successfully navigating these processes is crucial for bringing new products to market and maintaining existing approvals.
How does Orexo AB (publ) manage patent expiration risks?
Orexo AB (publ) manages patent expiration risks through a combination of strategies, including developing new formulations of existing products, expanding indications for existing products, and pursuing patent extensions. The company also invests in research and development to create new and innovative products with strong patent protection. By proactively managing its patent portfolio, Orexo aims to mitigate the impact of patent expirations and maintain its competitive advantage in the market.
What are the key factors to evaluate for ORXOF?
Orexo AB (publ) (ORXOF) currently holds an AI score of 50/100, indicating moderate score. Key strength: Specialized focus on opioid dependence and pain management.. Primary risk to monitor: Ongoing: Competition from generic alternatives to Zubsolv.. This is not financial advice.
How frequently does ORXOF data refresh on this page?
ORXOF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ORXOF's recent stock price performance?
Recent price movement in Orexo AB (publ) (ORXOF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized focus on opioid dependence and pain management.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for ORXOF.
- OTC market carries higher risks.
- Financial data based on available information and may be subject to change.